Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: EMD Serono, Massachusetts General Hospital; Rosetta Genomics; BioLegend, Covance

NEW YORK (GenomeWeb) – EMD Serono Research and Development Institute, a subsidiary of Merck KGaA, is collaborating with Massachusetts General Hospital to research systemic lupus erythematosus and lupus nephritis pathogenesis. Scientists from both organizations will work jointly to better characterize and validate the expression of investigative therapeutic targets, pathogenic immune cell types, and biomarkers in SLE and LN patients. Researchers at the hospital will collect biospecimens for translational research applications, such as gene expression analysis of target molecules, as well as compound testing. A major goal of the agreement is to generate supporting data on the role of certain proteins targeted by clinical-stage assets in the EMD Serono portfolio in LN pathogenesis and to enable early discovery work in immunology, EMD Serono said.

Rosetta Genomics announced the initiation of the Rosetta Cancer Origin Test Patient Registry study, a two-part global registry to evaluate the impact of the Cancer Origin Test on treatment decisions in patients diagnosed with metastatic cancers or cancers of unknown or uncertain primary. The study aims to track the selection of treatments, duration of response to therapies, survival, and other clinically relevant information. Data on the clinical outcomes of about 400 patients will be collected. MedPanel will conduct the study on behalf of Rosetta.

BioLegend acquired Covance's antibody business on Aug. 29 for an undisclosed amount. Covance Antibody Services develops and manufactures antibodies and research reagents for neuroscience, immunopathology, cell biology, epitope tags, and immunohistochemistry detection.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Filed under